Clearmind Medicine (NASDAQ:CMND) Announces Quarterly Earnings Results

Clearmind Medicine (NASDAQ:CMND) released its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, Zacks reports.

Clearmind Medicine Stock Performance

Shares of Clearmind Medicine stock opened at $1.14 on Friday. The firm has a market cap of $4.86 million, a P/E ratio of -0.61 and a beta of 1.02. The company has a current ratio of 1.72, a quick ratio of 1.72 and a debt-to-equity ratio of 0.01. Clearmind Medicine has a 12 month low of $0.95 and a 12 month high of $2.30. The stock’s fifty day moving average price is $1.35 and its 200-day moving average price is $1.36.

Clearmind Medicine Company Profile

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.